AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|
24.1 C
New York
Thursday, June 25, 2026

Tag: risk

newssourceFORcompanyinformationcontent1marketreleases

VolitionRx Announces Pricing of $4.6 Million Public Offering

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7,...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Bittam Launches No-KYC Crypto Perpetual Futures Trading with 200x Leverage and ＄100 Deposit Bonus

 NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- Bittam Exchange today announced the launch of a $300 New User Bonus for newly registered users, offering trading credits to eligible participants who complete account registration and initial trading activities on the platform.

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Cyndee Haydon Named Among 2026 Best Real Estate Agents in the United States by RealTrends, Ranking #723 in Florida Out of 232,000 Realtors

Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data 
Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRisk

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers